Circulating specific biomarkers in diagnosis of hepatocellular carcinoma and its metastasis monitoring

Tumor Biology

Volumn 35, Issue 1, 2014, Pages 9-20

  Wang, Li ^a   Yao, Min ^a   Dong, Zhizhen ^a   Zhang, Yun ^b   Yao, Dengfu ^a  

^a NANTONG UNIVERSITY   (China)

^b NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Diagnosis; Hepatocellular carcinoma; Monitoring metastasis; Postoperative recurrence; Specific biomarkers

Indexed keywords

ALPHA FETOPROTEIN; BIOLOGICAL MARKER; ENZYME; GAMMA GLUTAMYLTRANSFERASE; GLYCOPROTEIN; GLYPICAN 3; GOLGI GLYCOPROTEIN; HEAT SHOCK PROTEIN 27; HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN 90; MESSENGER RNA; MICRORNA; SOMATOMEDIN B; TELOMERASE; TRANSFORMING GROWTH FACTOR BETA1; TUMOR MARKER; TUMOR PROTEIN; UNCLASSIFIED DRUG; VASCULOTROPIN;

ACUTE HEPATITIS; ALPHA FETOPROTEIN BLOOD LEVEL; CANCER DIAGNOSIS; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SCREENING; CANCER STAGING; CANCER TISSUE; CHILD PUGH SCORE; CHRONIC HEPATITIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; EARLY DIAGNOSIS; GENE AMPLIFICATION; GENETIC MARKER; GENETIC TRANSCRIPTION; HEPATITIS B VIRUS; HUMAN; IMMUNOHISTOCHEMISTRY; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MALIGNANT TRANSFORMATION; METASTASIS; PATIENT MONITORING; PERIPHERAL BLOOD MONONUCLEAR CELL; POLYACRYLAMIDE GEL ELECTROPHORESIS; POSTOPERATIVE CARE; PREDICTIVE VALUE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SENSITIVITY AND SPECIFICITY; TUMOR VOLUME; WESTERN BLOTTING;

ALPHA-FETOPROTEINS; CARCINOMA, HEPATOCELLULAR; GAMMA-GLUTAMYLTRANSFERASE; GLYPICANS; HEAT-SHOCK PROTEINS; HUMANS; INSULIN-LIKE GROWTH FACTOR II; ISOENZYMES; LIVER NEOPLASMS; MICRORNAS; NEOPLASM METASTASIS; TELOMERASE; TRANSFORMING GROWTH FACTOR BETA; TUMOR MARKERS, BIOLOGICAL;

EID: 84894472826     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-013-1141-0     Document Type: Review

References (96)

1. Yang JD, Roberts LR. Hepatocellular carcinoma: a global view. Nat Rev Gastroenterol Hepatol. 2010;7(8):449-58. PMID: 20628345.
2. El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology. 2012;142(6):1264-73. PMID: 22537432.
3. Ni JY, Liu SS, Xu LF, Sun HL,ChenYT. Meta-analysis of radiofrequency ablation in combination with transarterial chemoembolization for hepatocellular carcinoma.World J Gastroenterol. 2013;19(24):3872-82. PMID: 23840128.
4. Wei Z, Doria C, Liu Y. Targeted therapies in the treatment of advanced hepatocellular carcinoma. Clin Med Insights Oncol. 2013;7(1):87-102. PMID: 23761989.
5. Jain S, Singhal S, Lee P, Xu R. Molecular genetics of hepatocellular neoplasia. Am J Transl Res. 2010;2(1):105-18. PMID: 20182587.
6. Kawakami M, Koda M, Mandai M, Hosho K, Murawaki Y, Oda W, et al. Isolated metastases of hepatocellular carcinoma in the right atrium: case report and review of the literature. Oncol Lett. 2013;5(5): 1505-8. PMID: 23760591.
7. Block TM, Marrero J, Gish RG, Sherman M, LondonWT, Srivastava S, et al. The degree of readiness of selected biomarkers for the early detection of hepatocellular carcinoma: notes from a recent workshop. Cancer Biomark. 2008;4(1):19-33. PMID: 18334731.
8. Volk ML, Hernandez JC, Su GL, Lok AS, Marrero JA. Risk factors for hepatocellular carcinoma may impair the performance of biomarkers: a comparison of AFP, DCP, and AFP-L3. Cancer Biomark. 2007;3(1):79-87. PMID: 17522429.
9. Hayashi E, Kuramitsu Y, Okada F, FujimotoM, Zhang X, Kobayashi M, et al. Protoemics profiling for cancer progression differential display analysis for the expression of intracellular proteins between regressive and progressive cancer cell lines. Proteomics. 2005;5(4): 1024-32. PMID: 15712240.
10. Chen F, Xue J, Zhou L, Wu S, Chen Z. Identification of serum biomarkers of hepatocarcinoma through liquid chromatography/ mass spectrometry-based metabonomic method. Anal Bioanal Chem. 2011;401(6):1899-904. PMID: 21833635.
11. Wu W, Yao DF, Yuan YM, Fan JW, Lu XF, Li XH, et al. Combined serum hepatoma-specific alpha-fetoprotein and circulating alpha-fetoprotein-mRNA in diagnosis of hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int. 2006;5(4):538-44. PMID: 17085339.
12. Kohles N, Nagel D, Jüngst D, Durner J, Stieber P, Holdenrieder S. Prognostic relevance of oncological serum biomarkers in liver cancer patients undergoing transarterial chemoembolization therapy. Tumour Biol. 2012;33(1):33-40. PMID: 21931992.
13. Qu KZ, Zhang K, Li H, Afdhal NH, Albitar M. Circulating microRNAs as biomarkers for hepatocellular carcinoma. J Clin Gastroenterol. 2011;45(4):355-60. PMID: 21278583.
14. Wang HL, Anatelli F, Zhai QJ, Adley B, Chuang ST, Yang XJ. Glypican-3 as a useful diagnostic marker that distinguishes hepatocellular carcinoma from benign hepatocellular mass lesions. Arch Pathol Lab Med. 2008;132(11):1723-8. PMID: 18976006.
15. Mao YL, Yang HY, Xu HF, Sang XT, Lu X, Yang ZY, et al. Significance of Golgi glycoprotein 73, a new tumor marker in diagnosis of hepatocellular carcinoma: a primary study. Chin Med J. 2008;88(14):945-51. PMID: 18756964.
16. Hu JS, Wu DW, Liang S, Miao XY. GP73, a resident Golgi glycoprotein, is sensibility and specificity for hepatocellular carcinoma of diagnosis in a hepatitis B-endemic Asian population. Med Oncol. 2010;27(2):339-45. PMID: 19399652.
17. Imbeaud S, Ladeiro Y, Zucman-Rossi J. Identification of novel oncogenes and tumor suppressors in hepatocellular carcinoma. Semin Liver Dis. 2010;30(1):75-86. PMID: 20175035.
18. Zinkin NT, Grall F, Bhaskar K, Otu HH, Spentzos D, Kalmowitz B, et al. Serum proteomics and biomarkers in hepatocellular carcinoma and chronic liver disease. Clin Cancer Res. 2008;14(2):470-7. PMID: 18223221.
19. Nouso K, Kobayashi Y, Nakamura S, Kobayashi S, Takayama H, Toshimori J, et al. Prognostic importance of fucosylated alphafetoprotein in hepatocellular carcinoma patients with low alphafetoprotein. J Gastroenterol Hepatol. 2011;26(7):1195-200. PMID: 21410750.
20. YuenMF, Lai CL. Serologicalmarkers of liver cancer. Best Pract Res Clin Gastroenterol. 2005;19(1):91-9. PMID:15757806.
21. Yoshida S, Kurokohchi K, Arima K, Masaki T, Hosomi N, Funaki T, et al. Clinical significance of lens culinaris agglutinin-reactive fraction of serum alpha-fetoprotein in patients with hepatocellular carcinoma. Int J Oncol. 2002;20(2):305-9. PMID: 11788893.
22. El-Serag HB, Kramer JR, Chen GJ, Duan Z, Richardson PA, Davila JA. Effectiveness of AFP and ultrasound tests on hepatocellular carcinoma mortality in HCV-infected patients in the USA. Gut. 2011;60(7):992-7. PMID: 21257990.
23. Li D, Mallory T, Satomura S. AFP-L3: a new generation of tumor marker for hepatocellular carcinoma. Clin Chim Acta. 2001;313(1): 15-9. PMID: 11694234.
24. Kusaba T. Relationship between lens culinaris agglutinin reactive alpha-fetoprotein and biological features of hepatocellular carcinoma. Kurume Med J. 1998;45(1):113-20. PMID: 9658760.
25. Cheng HT, Chang YH, Chen YY, Lee TH, Tai DI, Lin DY. AFP-L3 in chronic liver diseases with persistent elevation of alphafetoprotein. J Chin Med Assoc. 2007;70(8):310-7. PMID: 17698430.
26. Miyaaki H, Nakashima O, Kurogi M, Eguchi K, Kojiro M. Lens culinaris agglutinin-reactive alpha-fetoprotein and protein induced by vitamin K absence II are potential indicators of a poor prognosis: a histopathological study of surgically resected hepatocellular carcinoma. J Gastroenterol. 2007;42(12):962-8. PMID: 18085353.
27. Marubashi S, Nagano H,Wada H, Kobayashi S, Eguchi H, Takeda Y, et al. Clinical significance of alpha-fetoprotein mRNA in peripheral blood in liver resection for hepatocellular carcinoma. Ann Surg Oncol. 2011;18(8):2200-9. PMID: 21301972.
28. ZhangY, Li Q, LiuN, Song T, Liu Z, Guo R, et al. Detection ofMAGE- 1, MAGE-3 and AFP mRNA as multimarker by real-time quantitative PCR assay: a possible predictor of hematogenous micrometastasis of hepatocellular carcinoma. Hepatogastroenterology. 2008;55(88):2200-6. PMID: 19260505.
29. Montaser LM, Abbas OM, Saltah AM, Waked IA. Circulating AFP mRNA as a possible indicator of hematogenous spread of HCC cells: a possible association with HBV infection. J Egypt Natl Canc Inst. 2007;19(1):48-60. PMID: 18839035.
30. Debruyne EN, Delanghe JR. Diagnosing and monitoring hepatocellular carcinoma with alpha-fetoprotein: new aspects and applications. Clin Chim Acta. 2008;395(1):19-26. PMID: 18538135.
31. Carr BI, Pancoska P, Branch RA. Significance of increased serum GGTP levels in HCC patients. Hepatogastroenterology. 2010;57(101): 869-74. PMID: 21033244.
32. Wang NY, Zhang D, ZhaoW, Fang GX, Shi YL, Duan MH. Clinical application of an enzyme-linked immunosorbent assay detecting hepatoma-specific gamma-glutamyl transferase. Hepatol Res. 2009;39(10):979-87. PMID: 19624768.
33. Ju MJ, Qiu SJ, Fan J, Zhou J, Gao Q, Cai MY, et al. Preoperative serum gamma-glutamyl transferase to alanine aminotransferase ratio is a convenient prognostic marker for Child-Pugh A hepatocellular carcinoma after operation. J Gastroenterol. 2009;44(6):635-42. PMID: 19387533.
34. Morsi MI, Hussein AE, Mostafa M, El-Abd E, El-Moneim NA. Evaluation of tumour necrosis factor-alpha, soluble P-selectin, gamma-glutamyl transferase, glutathione S-transferase-pi and alpha-fetoprotein in patients with hepatocellular carcinoma before and during chemotherapy. Br J Biomed Sci. 2006;63(1):74-8. PMID: 16871999.
35. West MB, Hanigan MH. γ-Glutamyl transpeptidase is a heavily Nglycosylated heterodimer in HepG2 cells. Arch Biochem Biophys. 2010;504(2):177-81. PMID: 20831856.
36. Zhang JB, Chen Y, Zhang B, Xie X, Zhang L, Ge N, et al. Prognostic significance of serum gamma-glutamyl transferase in patients with intermediate hepatocellular carcinoma treated with transcatheter arterial chemoembolization. Eur J Gastroenterol Hepatol. 2011;23(9): 787-93. PMID: 21730869.
37. Yu ZJ, Yu JW, Cai W, Yuan HX, Li XY, Yuan Y, et al. Evaluation of HCPTd1, d14-double passaged intervening chemotherapy protocol for hepatocellular carcinoma. World J Gastroenterol. 2005;11(33): 5221-5. PMID: 16127757.
38. Yao DF, Huang ZW, Chen SZ, Huang JF, Lu JX, Xiao MB, et al. Diagnosis of hepatocellular carcinoma by quantitative detection of hepatoma-specific bands of serumgamma-glutamyltransferase. Am J Clin Pathol. 1998;110(6):743-9. PMID: 9844586.
39. Yao DF, Jiang DR, Huang ZW, Lu JX, Tao QY, Yu ZJ, et al. Abnormal expression of hepatoma specific γ-glutamyl transferase and alteration of γ-glutamyl transferase gene methylation status in patients with hepatocellular carcinoma. Cancer. 2000;88(4):761-9. PMID: 10679644.
40. YaoDF, Dong ZZ,YaoDB,Wu XH,WuW, Qiu LW, et al. Abnormal expression of hepatoma-derived gamma-glutamyltransferase subtyping and its early alteration for carcinogenesis of hepatocytes. Hepatobiliary Pancreat Dis Int. 2004;3(4):564-70. PMID: 15567746.
41. Tang QY, Yao DF, Lu JX, Wu XH, Meng XY. Expression and alterations of different molecular form gamma-glutamyl transferase and total RNA concentration during the carcinogenesis of rat hepatoma. World J Gastroenterol. 1999;5(4):356-8 [ PMID: 11819467].
42. Filmus J, CapurroM. The role of glypican-3 in the regulation of body size and cancers. Cell Cycle. 2008;7(18):2787-90. PMID: 18787398.
43. Shafizadeh N, Ferrell LD, Kakar S. Utility and limitations of glypican-3 expression for the diagnosis of hepatocellular carcinoma at both ends of the differentiation spectrum.Mod Pathol. 2008;21(8): 1011-8. PMID: 18536657.
44. Yao M, Yao DF, Bian YZ, Wu W, Yan XD, Yu DD, et al. Values of circulating GPC-3 mRNA and alpha-fetoprotein in detecting patients with hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int. 2013;12(2):171-9. PMID: 23558072.
45. Nassar A, Cohen C, Siddiqui MT. Utility of glypican-3 and survivin in differentiating hepatocellular carcinoma from benign and preneoplastic hepatic lesions and metastatic carcinomas in liver fine-needle aspiration biopsies. Diagn Cytopathol. 2009;37(9):629-35. PMID: 19405109.
46. Yao M, Yao DF, Bian YZ, Zhang CG, Qiu LW, Wu W, et al. Oncofetal antigen glypican-3 as a promising early diagnostic marker for hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int. 2011;10(3):289-94. PMID: 21669573.
47. Yan D, He Q, Chen Y,Wang L, Zhang X. Detection of α-fetoprotein and glypican-3 mRNAs in the peripheral blood of hepatocellular carcinoma patients by using multiple FQ-RT-PCR. J Clin Lab Anal. 2011;25(2):113-7. PMID: 21438004.
48. Qiao SS, Cui ZQ, Gong L, Han H, Chen PC, Guo LM, et al. Simultaneous measurements of serum AFP, GPC-3 and HCCR for diagnosing hepatocellular carcinoma. Hepatogastroenterology. 2011;58(110-111):1718-24. PMID: 21940340.
49. Shirakawa H, Suzuki H, Shimomura M, Kojima M, Gotohda N, Takahashi S, et al. Glypican-3 expression is correlated with poor prognosis in hepatocellular carcinoma. Cancer Sci. 2009;100(8): 1403-7. PMID: 19496787.
50. Kandil D, Leiman G, Allegretta M, Trotman W, Pantanowitz L, Goulart R, et al. Glypican-3 immunocytochemistry in liver fineneedle aspirates: a novel stain to assist in the differentiation of benign and malignant liver lesions. Cancer. 2007;111(5):316-22. PMID: 17763368.
51. Scharf JG, Dombrowski F, Ramadori G. The IGF axis and hepatocarcinogenesis. Mol Pathol. 2001;54(3):138-44. PMID: 11376124.
52. Blobe GC, Schiemann WP, Lodish HF. Role of transforming growth factor beta in human disease. N Engl J Med. 2000;342(18):1350-8. PMID: 10793168.
53. Bissell DM, Roulot D, George J. Transforming growth factor beta and the liver. Hepatology. 2001;34(5):859-67. PMID: 11679955.
54. Lee D, Chung YH, Kim JA, Lee YS, Lee D, Jang MK, et al. Transforming growth factor beta 1 overexpression is closely related to invasiveness of hepatocellular carcinoma. Oncology. 2012;82(1): 11-8. PMID: 22269311.
55. Divella R, DanieleA,Gadaleta C, TufaroA,VenneriMT, Paradiso A, et al. Circulating transforming growth factor-β and epidermal growth factor receptor as related to virus infection in liver carcinogenesis. Anticancer Res. 2012;32(1):141-5. PMID: 22213299.
56. Morris SM, Baek JY, Koszarek A, Kanngurn S, Knoblaugh SE, Grady WM. Transforming growth factor-beta signaling promotes hepatocarcinogenesis induced by p53 loss. Hepatology. 2012;55(1): 121-31. PMID: 21898503.
57. Yamazaki K, Masugi Y, Sakamoto M. Molecular pathogenesis of hepatocellular carcinoma: altering transforming growth factor-β signaling in hepatocarcinogenesis. Dig Dis. 2011;29(3):284-8. PMID: 21829019.
58. Hoshida Y. Molecular signatures and prognosis of hepatocellular carcinoma. Minerva Gastroenterol Dietol. 2011;57(3):311-22. PMID:21769080.
59. Dong ZZ, Yao DF, Yao M, Qiu LW, Zong L, Wu W, et al. Clinical impact of plasma TGF-beta1 and circulating TGF-beta1 mRNA in diagnosis of hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int. 2008;7(3):288-95. PMID: 18522884.
60. Dong ZZ, Yao DF, Zou L, Yao M, Qiu LW, Wu XH, et al. An evaluation of transforming growth factor-beta 1 in diagnosing hepatocellular carcinoma and metastasis. Zhonghua Gan Zang Bing Za Zhi. 2007;15(7):503-8. Chinese [PMID: 17669238].
61. Scharf JG, Braulke T. The role of the IGF axis in hepatocarcinogenesis. Horm Metab Res. 2003;35(11-12):685-93. PMID: 14710347.
62. Rehem RN, El-Shikh WM. Serum IGF-1, IGF-2 and IGFBP-3 as parameters in the assessment of liver dysfunction in patients with hepatic cirrhosis and in the diagnosis of hepatocellular carcinoma. Hepatogastroenterology. 2011;58(108-108):949-54. PMID: 21830422.
63. Cantarini MC, de la Monte SM, Pang M, Tong M, D'Errico A, Trevisani F, et al. Aspartyl-asparagyl beta hydroxylase overexpression in human hepatoma is linked to activation of insulin-like growth factor and notch signaling mechanisms. Hepatology. 2006;44(2):446-57. PMID: 16871543.
64. Wang Z, Ruan YB, Guan Y, Liu SH. Expression of IGF-II in early experimental hepatocellular carcinomas and its significance in early diagnosis. World J Gastroenterol. 2003;9(2):267-70. PMID: 12532445.
65. Qiu LW, Yao DF, Zong L, Lu YY, Huang H,Wu W, et al. Abnormal expression of insulin-like growth factor-II and its dynamic quantitative analysis at different stages of hepatocellular carcinoma development. Hepatobiliary Pancreat Dis Int. 2008;7(4):406-11. PMID: 18693177.
66. Dong ZZ, Yao DF, Yao DB, Wu XH, Wu W, Qiu LW, et al. Expression and alteration of insulin-like growth factor II-messenger RNA in hepatoma tissues and peripheral blood of patients with hepatocellular carcinoma. World J Gastroenterol. 2005;11(30): 4655-60. PMID: 16094705.
67. Yao DF, Dong ZZ, Liu YH, Zhao L, Huang JF, Meng XY. Amplification of peripheral blood insulin-like growth factor IImRNA and its clinical significance in the diagnosis of hepatocellular carcinoma. Zhonghua Gan Zang Bing Za Zhi. 2003;11(11):695-6. Chinese [PMID: 14636457].
68. Qian J, Yao D, Dong Z,WuW, Qiu L, Yao N, et al. Characteristics of hepatic IGF-II expression and monitored levels of circulating IGF-II mRNA in metastasis of hepatocellular carcinoma. Am J Clin Pathol. 2010;134(5):799-806. PMID: 20959664.
69. Dong ZZ, Yao DF, Wu XH, Shi GS, Qiu LW, Wu W, et al. Early diagnostic value of abnormal expression of insulin-like growth factor (IGF)-II and IGF-II mRNA in hepatocellular carcinoma patients. Zhonghua Gan Zang Bing Za Zhi. 2005;13(11):866-8. Chinese [PMID: 16313745].
70. Daniel M, Peek GW, Tollefsbol TO. Regulation of the human catalytic subunit of telomerase (hTERT). Gene. 2012;498(2):135-46. PMID:22381618.
71. Satyanarayana A, Manns MP, Rudolph KL. Telomeres and telomerase: a dual role in hepatocarcinogenesis. Hepatology. 2004;40(2): 276-83. PMID: 15368430.
72. Mu J, Wei LX. Telomere and telomerase in oncology. Cell Res. 2002;12(1):1-7. PMID: 11942406.
73. Durant ST. Telomerase-independent paths to immortality in predictable cancer subtypes. J Cancer. 2012;3(1):67-82. PMID: 22315652.
74. Lewis KA,WuttkeDS. Telomerase and telomere-associated proteins: structural insights into mechanism and evolution. Structure. 2012;20(1):28-39. PMID: 22244753.
75. Yao DF, Wu W, Yao M, Qiu LW, Wu XH, Su XQ, et al. Dynamic alteration of telomerase expression and its diagnostic significance in liver or peripheral blood for hepatocellular carcinoma. World J Gastroenterol. 2006;12(31):4966-72. PMID:16937491.
76. Wu W, Yao DF, Qiu LW, Wu XH, Yao M, Su XQ, et al. Abnormal expression of hepatomas and circulating telomerase and its clinical values. Hepatobiliary Pancreat Dis Int. 2005;4(4):544-9. PMID: 16286259.
77. Ciocca DR, Calderwood SK. Heat shock proteins in cancer: diagnostic, prognostic, predictive, and treatment implications. Cell Stress Chaperones. 2005;10(2):86-103. PMID: 16038406.
78. Lu WJ, Lee NP, Fatima S, Luk JM. Heat shock proteins in cancer: signaling pathways, tumor markers and molecular targets in liver malignancy. Protein Pept Lett. 2009;16(5):508-16. PMID: 19442230.
79. Sakamoto M, Mori T, Masugi Y, Effendi K, Rie I, Du W. Candidate molecular markers for histological diagnosis of early hepatocellular carcinoma. Intervirology. 2008;51(1):42-5. PMID: 18544947.
80. Wu XH, Yao DF, Su XQ, Tai BJ, Huang H, Qiu LW, et al. Dynamic expression of rat heat shock protein gp96 and its gene during development of hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int. 2007;6(6):616-21. PMID: 18086628.
81. Yao DF, Wu XH, Su XQ, Yao M, Wu W, Qiu LW, et al. Abnormal expression of HSP gp96 associated with HBV replication in human hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int. 2006;5(3): 381-6. PMID: 16911935.
82. Luk JM, Lam CT, Siu AF, Lam BY, Ng IO, Hu MY, et al. Proteomic profiling of hepatocellular carcinoma in Chinese cohort reveals heatshock proteins (Hsp27, Hsp70, GRP78) up-regulation and their associated prognostic values. Proteomics. 2006;6(3):1049-57. PMID: 16400691.
83. Joo M, Chi JG, Lee H. Expressions of HSP70 and HSP27 in hepatocellular carcinoma. J Korean Med Sci. 2005;20(5):829-34. PMID: 16224158.
84. Kojima K, Takata A, Vadnais C, Otsuka M, Yoshikawa T, Akanuma M, et al. MicroRNA122 is a key regulator of α-fetoprotein expression and influences the aggressiveness of hepatocellular carcinoma. Nat Commun. 2011;2(2):338. PMID: 21654638.
85. Gui J, Tian Y, Wen X, Zhang W, Zhang P, Gao J, et al. Serum microRNA characterization identifies miR-885-5p as a potential marker for detecting liver pathologies. Clin Sci. 2011;120(5):183-93. PMID: 20815808.
86. Effendi K, Sakamoto M. Molecular pathology in early hepatocarcinogenesis. Oncology. 2010;78(2):157-60. PMID: 20389138.
87. Augello C, Vaira V, Caruso L, Destro A, Maggioni M, Park YN, et al. MicroRNA profiling of hepatocarcinogenesis identifies C19MC cluster as a novel prognostic biomarker in hepatocellular carcinoma. Liver Int. 2012;32(5):772-82. PMID: 22429613.
88. Giordano S, Columbano A. MicroRNAs: new tools for diagnosis, prognosis, and therapy in hepatocellular carcinoma? Hepatology. 2013;57(2):840-7. PMID: 23081718.
89. Zhao X, Yang Z, Li G, Li D, Zhao Y, Wu Y, et al. The role and clinical implications of microRNAs in hepatocellular carcinoma. Sci China Life Sci. 2012;55(10):906-19. PMID: 23108868.
90. Liao SF, Yang HI, Lee MH, Chen CJ, Lee WC. Fifteen-year population attributable fractions and causal pies of risk factors for newly developed hepatocellular carcinomas in 11,801 men in Taiwan. PLoS One. 2012;7(4):e34779. PMID: 22506050.
91. Gish RG, Lencioni R, Di Bisceglie AM, Raoul JL, Mazzaferro V. Role of the multi-disciplinary team in the diagnosis and treatment of hepatocellular carcinoma. Expert Rev Gastroenterol Hepatol. 2012;6(2):173-85. PMID: 22375523.
92. Wong VW, Chan HL. Prevention of hepatocellular carcinoma: a concise review of contemporary issues. Ann Hepatol. 2012;11(3): 284-93. PMID: 22481445.
93. Abdalla M A, Haj-Ahmad Y. Promising candidate urinaryMicroRNA biomarkers for the early detection of hepatocellular carcinoma among high-risk hepatitis C virus Egyptian patients. J Cancer. 2012;3(1):19-31. PMID: 22211142.
94. Kohles N, Nagel D, Jüngst D, Durner J, Stieber P, Holdenrieder S. Relevance of circulating nucleosomes and oncological biomarkers for predicting response to transarterial chemoembolization therapy in liver cancer patients. BMC Cancer. 2011;11(1):202. PMID: 21615953.
95. Oda K, Ido A, Tamai T, Matsushita M, Kumagai K, Mawatari S, et al. Highly sensitive lens culinaris agglutinin-reactive α-fetoprotein is useful for early detection of hepatocellular carcinoma in patients with chronic liver disease. Oncol Rep. 2011;26(5):1227-33. PMID: 21874252.
96. Petrelli A, Perra A, Schernhuber K, Cargnelutti M, Salvi A, Migliore C, et al. Sequential analysis of multistage hepatocarcinogenesis reveals that miR-100 and PLK1 dysregulation is an early event maintained along tumor progression. Oncogene. 2012;31(42):4517-26. PMID: 22249248